BTT-105 ameliorates hepatic fibrosis in non-alcoholic fatty liver animal model.

Autor: Kim HY; Department of Translational Medicine, Hanyang University Graduate School of Biomedical Science and Engineering, Seoul, Republic of Korea., Ahn SB; Department of Internal Medicine, Eulji University School of Medicine, Seoul, Republic of Korea., Hong JM; Biotoxtech Co., Ltd., Cheongju, Republic of Korea., Oh JH; Department of Translational Medicine, Hanyang University Graduate School of Biomedical Science and Engineering, Seoul, Republic of Korea., Saeed WK; Department of Internal Medicine, Hanyang University School of Medicine, Seoul, Republic of Korea., Kim GS; Biotoxtech Co., Ltd., Cheongju, Republic of Korea., Kim H; Biotoxtech Co., Ltd., Cheongju, Republic of Korea., Kang JK; Biotoxtech Co., Ltd., Cheongju, Republic of Korea., Kang S; Biotoxtech Co., Ltd., Cheongju, Republic of Korea., Jun DW; Department of Translational Medicine, Hanyang University Graduate School of Biomedical Science and Engineering, Seoul, Republic of Korea.; Department of Internal Medicine, Hanyang University School of Medicine, Seoul, Republic of Korea.
Jazyk: angličtina
Zdroj: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2021 Nov; Vol. 35 (11), pp. e21979.
DOI: 10.1096/fj.202002656RRR
Abstrakt: BTT-105 (1-O-hexyl-2,3,5-trimethylhydroquinone), a hydroquinone derivative, is a potent anti-oxidant that was safe and tolerable in phase I clinical trial. This study examined the anti-fibrotic effect of BTT-105 in a mouse model of non-alcoholic fatty liver disease (NAFLD) along with the underlying mechanisms. In vivo, efficacy of BTT-105 evaluated from three kinds of NAFLD models (methionine/choline deficient diet (MCD), high fat diet (HF) and western diet (WD)). Metabolomics and transcriptomics profiling analysis in liver tissues were conducted. In vitro, anti-fibrotic effect of BTT-105 assessed in human hepatic stellated cells (HSCs) and primary mouse HSCs. BTT-105 improved NAFLD activity score in three kinds of NAFLD animal models (MCD, HF, and WD). BTT-105 also decreased levels of hepatic pro-collagen and collagen fibers deposition in liver tissue. Metabolome and transcriptome analysis revealed that BTT-105 decreased lipid metabolites and increased antioxidants in NAFLD mice. In HepG2 cells, BTT-105 enhanced Nrf2-ARE reporter activity in a dose-dependent manner and increased the levels of antioxidant gene expression. BTT-105 showed inhibition of HSCs activation and migration. Gene expression profiling and protein expression showed that BTT-105 increased Nrf2 activation as well as decreased PI3K-Akt pathway in activated HSCs. BTT-105 attenuated ameliorates steatohepatitis and hepatic fibrosis.
(© 2021 Federation of American Societies for Experimental Biology.)
Databáze: MEDLINE
Externí odkaz: